Stryker has entered a definitive agreement to acquire medical device company Inari Medical for approximately $4.9 billion.
Inari was founded in 2011 and focuses on mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism, according to a Jan. 6 press release.
The acquisition is intended to complement Stryker's neurovascular business. Inari provides solutions for VTE clot removal without the use of thrombolytic drugs.
Under the agreement terms, Stryker will commence a tender offer for all outstanding shares of common stock of Inari for $80 per share in cash. The boards of both Stryker and Inari have unanimously approved the acquisition.
The transaction is expected to close by the end of the first quarter of 2025, according to the release.